Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy

Monoclonal antibody-based therapy has achieved great success and is now one of the most crucial therapeutic modalities for cancer therapy. The first monoclonal antibody authorized for treating human epidermal growth receptor 2 (HER2)-positive breast cancer is trastuzumab. However, resistance to tras...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Zhihui, Huang, Zhuoshan, Li, Senlin, Wang, Ying, Yao, Yandan, Yang, Xianzhu, Xu, Xiaoding
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031380/
https://www.ncbi.nlm.nih.gov/pubmed/36970191
http://dx.doi.org/10.1016/j.apsb.2022.09.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031380/
https://www.ncbi.nlm.nih.gov/pubmed/36970191
http://dx.doi.org/10.1016/j.apsb.2022.09.021

Ejemplares similares